EMA Recommends Extension of Indications for Pirtobrutinib By Ogkologos - April 24, 2025 504 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory chronic lymphocytic leukaemia Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Camrelizumab Plus Rivoceranib Improves Survival Compared with Sorafenib in First-Line Treatment... August 2, 2023 The Best And Worst Face Masks For COVID-19, Plus Face Masks... August 19, 2020 Machine Learning-Based Model Shows Promise for Indicating Response to Immune Checkpoint... December 9, 2020 Learning From Being Lost July 14, 2021 Load more HOT NEWS ΚΑΡΚΙΝΟΣ ΠΝΕΥΜΟΝΑ RANO and Modified RANO Criteria Demonstrate Similar Correlations Between PFS and... Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... Are Cancer Patients Getting the Opioids They Need to Control Pain?
